- Report
- December 2024
Japan, United States, ... Japan, United States, Europe
From €16255EUR$18,500USD£14,022GBP
- Report
- January 2025
- 132 Pages
Global
From €835EUR$950USD£720GBP
- Report
- January 2025
- 132 Pages
Global
From €835EUR$950USD£720GBP
- Report
- September 2024
- 121 Pages
China
From €1582EUR$1,800USD£1,364GBP
- Report
- July 2024
- 99 Pages
China
From €1582EUR$1,800USD£1,364GBP
- Report
- March 2024
- 132 Pages
Global
From €835EUR$950USD£720GBP
- Report
- November 2021
- 747 Pages
Global
From €3515EUR$4,000USD£3,032GBP
- Report
- November 2021
- 620 Pages
Global
From €3515EUR$4,000USD£3,032GBP
- Report
- November 2021
- 365 Pages
Global
From €3075EUR$3,500USD£2,653GBP
- Book
- November 2024
- 464 Pages
- Book
- March 2024
- 496 Pages
- Book
- May 2023
- 512 Pages
- Book
- April 2023
- 2000 Pages
- Book
- February 2023
- 448 Pages

The Monoclonal Antibodies market is a subset of the biotechnology industry that focuses on the production and use of monoclonal antibodies (mAbs). mAbs are laboratory-produced proteins that are designed to bind to specific targets, such as proteins, cells, or tissues. They are used in a variety of applications, including diagnostics, therapeutics, and research.
The market for mAbs is growing rapidly, driven by advances in biotechnology and the increasing demand for personalized medicine. mAbs are used in a variety of treatments, including cancer, autoimmune diseases, and infectious diseases. They are also used in research to develop new treatments and to improve existing treatments.
The market for mAbs is highly competitive, with many companies offering a wide range of products. Major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are investing heavily in research and development to develop new mAbs and to improve existing products.
In conclusion, the Monoclonal Antibodies market is an important part of the biotechnology industry, with many companies investing heavily in research and development to develop new products and improve existing treatments. Major players in the market include AbbVie, Amgen, AstraZeneca, Show Less Read more